Indivior Share Discussion Threads

[casholaa] 10/11/2023 17:12

Over the last 3 years or so, my stops have kicked in at least 3 times. I've learnt it gives way a lot when it moves in either direction.

[gregmorg] 10/11/2023 16:43

Well I listened quite intensely to the company and to the Q and A which can highlight any added theme but didn’t get any unknowns popping up . Maybe the bears in this market are the only active participants!

[gregmorg] 10/11/2023 16:43

Well I listened quite intensely to the company and to the Q and A which can highlight any added theme but didn’t get any unknowns popping up . Maybe the bears in this market are the only active participants!

[redwing1] 10/11/2023 16:16

Steeplejack - I don't think the post from ShearClass does sum things up very well. They are wide of the mark with suboxone because the entry of a 4th generic competitor has been pushed back later in the year more than once and hence suboxone sales have held up ok. The generic competition is already well known and is becoming less relevant each quarter as Sublocade grows. Sublocade and Perseris will account for at least $645m out of a total c$1050m sales this year.

Perseris guidance is a small negative but not that significant and I suspect it is too early to talk about the Opvee launch.

The impact of the recent legal settlement on the balance sheet should be well known and still leaves Indivior with net cash to pay the remaining DOJ instalments.

Something has obviously spooked the institutions from the conference call but I can't fathom what. Looks oversold to me.

[elsa7878] 10/11/2023 16:00

Am right in thinking that the total liabilities and provisions at the moment equate to $880 million. $440m provisions (DP class settlement etc) and $440m liabilities (DOJ. etc). Cash $610 m (plus $160m in investments).
Thanks.

[gregmorg] 10/11/2023 13:54

Listened to the webcast and everything seemed Okay but nothing more than that-- didn't have a buzz, one was or the other, at the end of it.

I admit I did think it could drift for a while as there was no added aspect that one could focus on. Not the first time with Indivior's 3rd quarter results that I recall.

Perseris sales, from a low overall group base were fine that I can see - very much in line but the annual guidance was adjusted to a lower end of earlier projected range because of some new competing product launch but appeared no big deal. Longer term hopes still very positive. Yet product potential not big in the context of the whole. Sublocade growth going along well.

Added costs and provisions were to be expected so a 3rd quarter loss was inevitable.My take is these overall markets take no prisoners and an element of throwing in the towel and capitulation is upon us. Historically that's often an interesting time. Not enjoying this after the years and years of tribulations but we will see.

[steeplejack] 10/11/2023 11:26

I've taken this from LSE.Post by ShearClass.It sums things up succinctly i think. I suspect it's due to a multitude of factors; - Sublingual revenues seeing a rapid decline YoY, offsetting Sublocade increases - Below expectations performance of Perseris - No detail on Opvee launch / revenue expectations - Market digesting the balance sheet impact of the massive final settlement & not liking what it sees Ultimately, operating profit is running at ~$225m PA, what we don't know is how much of that is related to sublingual. If revenues continue to decline there as expected, then without a major Opvee launch the top line growth will stall. Essentially things are in the balance, however sentiment has turned negative due to the above factors. Downtrend support sits at ~£11.80 as far as I se

[elsa7878] 10/11/2023 11:11

Not a holder but must be a broker downgrade. Selling started as the conference call started yesterday so must be something that was said.

[liam1om] 10/11/2023 08:19

Second biggest faller on the FTSE350 today. Amazing.

[dealy] 10/11/2023 08:18

incredible that it hits a 52 week low despite making huge progress

[liam1om] 10/11/2023 08:15

Down another 5% and through support here. Needs to bounce today or it could get nasty.

[ariane] 10/11/2023 06:26

Indivior swings to quarterly loss on costs despite strong sales
November 09, 2023 at 10:56 am
Share

(Alliance News) - Indivior PLC on Thursday maintained net revenue guidance, after swinging to a net loss despite seeing a sales increase in the third quarter.

For the three months ended September 30, the Virginia-headquartered pharmaceutical company reported net revenue of USD271 million, up 17% from USD232 million a year prior.

During the third quarter, US revenue rose 20% to USD227 million from USD189 million. Meanwhile, Rest of World revenue grew 2% to USD44 million from USD43 million the previous year.

By contrast, Indivior posted a net loss of USD135 million for the quarter, swung from net income of USD41 million year-on-year. Pretax loss was USD181 million, swung from profit of USD54 million.

Diluted loss per share was USD0.98, swung from earnings per share of USD0.29 a year prior.

Losses came amid higher expenses. While research and development costs were marginally lower year-on-year at USD18 million from USD20 million, selling, general and administrative expenses rose to USD390 million from USD115 million.

Earlier in October, Indivior reached an agreement to resolve claims brought by the direct purchasers in an antitrust multi-district litigation.

The litigation was centred on the claim that the pharmaceutical company stymied generic competition for the opioid addiction treatment Suboxone, in order to preserve its dominance.

Indivior agreed to pay USD385 million and book a charge of USD228 million in the third quarter, though said this would be excluded from adjusted earnings. Payment is expected to be made in November, and funded from existing cash.

"This quarter has again demonstrated the commitment and capabilities of the Indivior team. We delivered double-digit top-line performance led by strong growth of SUBLOCADE (buprenorphine extended release), which continues to shift the paradigm for the treatment of opioid use disorder," said Chief Executive Officer Mark Crossley.

"Additionally, we made good progress against our strategic priorities, with the launch of OPVEE (nalmefene) nasal spray as well as key transactions to strengthen our pipeline and to secure long-term product supply," Crossley added.

Looking ahead, the firm continues to expect full year net revenue in the range of USD1.03 billion to USD1.09 billion, reflecting growth of 18% at the mid-point compared with the previous year.

Within the total, it now expects Sublocade net revenue to be USD610 million to USD630 million, versus the previous range of USD590 million to USD630 million, based on continued strong performance in the OHS channel.

Perseris net revenue is now expected to be at the lower end of the USD45 million to USD55 million guidance range, reflecting year-to-date results and near-term competitive pressures.

Costs are expected to be higher, with selling, general and administrative expenses anticipated between USD540 million and USD550 million, from previous guidance of USD530 million to USD540 million.

Overall, Indivior continues to expect adjusted operating profit to be higher than the previous financial year's USD212 million.

Indivior shares were trading 1.8% lower at 1,511.00 pence each in London on Thursday morning.

By Holly Beveridge, Alliance News reporter

Comments and questions to [e-mail]

[steeplejack] 09/11/2023 21:03

Only closed down 5.5% on the street.

[villarich] 09/11/2023 17:53

Absolute madness. Literally the same message but with the numbers.

[youngers] 09/11/2023 16:17

I love how the company announces last month the settlement amount and the market thinks oh good that’s all sorted. Then they announce results with the same settlement in and market falls out of bed.

[casholaa] 09/11/2023 15:30

Unfortunately, I think the share price may trickle downward for a while now. That's the 'markets' for you.

[faz] 09/11/2023 15:27

THe bottom line cost for the settlement was spelt our three weeks ago, so no one should be surprised. But clearly a number of people cant do joined up thinking. It's behind them now and I see this as a buying opportunity, not a time to sell.

[gregmorg] 09/11/2023 14:15

A decent set of 3rd quarter figures and encouraging signals but headline operating losses after a whole raft of additional items, initial product launch costs and legal settlements included, sort of take any shine off. I had hoped the additional US listing would mark a new exciting chapter but that appears not to be-- for now!

[casholaa] 09/11/2023 13:12

I just got stopped out.

[youngers] 09/11/2023 10:26

Indeed, strong revenue growth continuing which can only bode well for future profitability. Looking forward to the 2024 outlook in the q4 results.

Also great to see the product diversification improving too.

[steeplejack] 09/11/2023 10:03

Results and commentary look solid.

[ariane] 09/11/2023 07:38

SLOUGH, United Kingdom and RICHMOND, Va., Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.

Indivior (PRNewsfoto/Indivior)

The earnings release can be found at www.indivior.com/investors

The investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)

There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below.

Webcast link:
Participants may access the presentation telephonically by registering with the following link: [...]

[steeplejack] 23/10/2023 09:19

We can only hope that's an end to it but we all know that lawyers are always on the sniff for a remunerative case.